According to Dr. Yiu, this is the first study to show an anatomic change in the suprachoroidal space that may correspond to the effects of suprachoroidal drug delivery.
Nevertheless, Dr. Yiu cautions that it is unclear if the expansion represents persistent drug remaining in the suprachoroidal space or mechanical or pharmacologic changes caused by the drug injection.
Preclinical animal studies have shown a 90-day window when suprachoroidally injected triamcinolone can be detected. The possibility that OCT imaging may be used to follow suprachoroidal drug delivery is intriguing.
"Our findings provide novel insights into the ocular distribution and anatomic effects of suprachoroidal injection of triamcinolone acetonide suspension in patients with macular edema due to RVO. The suprachoroidal space influences both posterior and anterior segment disease processes, and continues to be a target for new interventions, including glaucoma drainage devices, IOP monitoring, and injections of pharmacologic agents. The advantages of suprachoroidal drug administration include the reduction of anterior segment exposure, lower risk of cataracts and glaucoma, and potentially more targeted or sustained drug delivery for treatment of retinal conditions," the investigators commented.
Glenn Yiu, MD, PhD
E: [email protected]
This article was reviewed by Dr. Yiu. Dr. Yiu has no financial interest in any aspect of this report.